Interobserver agreement of radiologists assessing the response of rectal cancers to preoperative chemoradiation using the MRI tumour regression grading (mrTRG) by Siddiqui, MRS et al.
Accepted Manuscript
Inter-observer agreement of radiologists assessing the response of rectal cancers to
pre-operative chemoradiation using the MRI tumour regression grading (mrTRG)
M.R.S. Siddiqui, K.L. Gormly, J. Bhoday, S. Balyansikova, N.J. Battersby, M. Chand,
S. Rao, P. Tekkis, A.M. Abulafi, G. Brown, Professor
PII: S0009-9260(16)30072-1
DOI: 10.1016/j.crad.2016.05.005
Reference: YCRAD 4361
To appear in: Clinical Radiology
Received Date: 14 October 2015
Revised Date: 13 March 2016
Accepted Date: 3 May 2016
Please cite this article as: Siddiqui MRS, Gormly KL, Bhoday J, Balyansikova S, Battersby NJ, Chand M,
Rao S, Tekkis P, Abulafi AM, Brown G, Inter-observer agreement of radiologists assessing the response
of rectal cancers to pre-operative chemoradiation using the MRI tumour regression grading (mrTRG),
Clinical Radiology (2016), doi: 10.1016/j.crad.2016.05.005.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
MANUSCRIPT TITLE PAGE 
 
Inter-observer agreement of radiologists assessing the response of rectal cancers to pre-
operative chemoradiation using the MRI tumour regression grading (mrTRG). 
 
Author list  
 
1) Muhammed Rafay Sameem Siddiqui1,2,6 
2) Kirsten L Gormly4 
3) Jemma Bhoday1,2,6 
4) Svetlana Balyansikova2 
5) Nicholas J Battersby2 
6) Manish Chand5 
7) Sheela Rao2 
8) Paris Tekkis3,6 
9) Al-Mutaz Abulafi1 
10) Gina Brown2,6 
 
Affiliations 
 
1 Department of Colorectal Surgery, Croydon University Hospital, Croydon, UK, CR7 7YE.  
2Department of Radiology, Royal Marsden Hospital, Sutton, Surrey, UK, SM2 5PT.  
3Department of Surgery, Royal Marsden Hospital, Fulham Rd, London, UK, SW3 6JJ. 
4Dr Jones and Partners, Adelaide, South Australia. 
5Department of Surgery, University College London, London, UK 
6Imperial College London, London, UK 
 
Corresponding author: 
Professor Gina Brown  
Department of Radiology, The Royal NHS Foundation Trust, Downs Road, Sutton, Surrey, 
SM2 5PT. 
Phone: 0208 915 6067 
Fax:  0208 915 6721  
E-mail:gina.brown@rmh.nhs.uk 
 
Funding: 
The corresponding author is funded by a grant from the pelican center 
 
Contributors: 
Karen Thomas, Statistician, Royal Marsden Hospital, UK 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Interobserver agreement of radiologists assessing the response of rectal cancers to 
preoperative chemoradiation using the MRI tumour regression grading (mrTRG) 
 
M. R. S. Siddiqui1,2,6, K. L. Gormly4, J. Bhoday1,2,6, S. Balyansikova2, N. J. 
Battersby2, M. Chand5, S. Rao2, P Tekkis3,6, A.-M. Abulafi1, G. Brown2,6 
 
1 Department of Colorectal Surgery, Croydon University Hospital, Croydon CR7 7YE, 
UK  
2Department of Radiology, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK  
3Department of Surgery, Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, UK 
4Dr Jones and Partners, Adelaide, South Australia 
5Department of Surgery, University College London, London, UK 
6Imperial College London, London, UK 
 
*Guarantor and correspondent: G. Brown, Department of Radiology, The Royal NHS 
Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK. Tel.: 0208 915 6067; 
fax: 0208 915 6721.  
E-mail address: gina.brown@rmh.nhs.uk 
 
ABSTRACT 
AIM: To investigate whether the magnetic resonance imaging (MRI) tumour 
regression grading (mrTRG) scale can be taught effectively resulting in a clinically 
reasonable interobserver agreement (κ>0.4; moderate to near perfect agreement). 
MATERIALS AND METHODS: This study examines the interobserver agreement of 
mrTRG, between 35 radiologists and a central reviewer. Two workshops were 
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organised for radiologists to assess regression of rectal cancers on MRI staging 
scans. A range of mrTRGs on 12 patient scans were used for assessment. 
RESULTS: Kappa agreement ranged from 0.14–0.82 with a median value of 0.57 
(95% CI: 0.37–0.77) indicating good overall agreement. Eight (26%) radiologists had 
very good/near perfect agreement (κ>0.8). Six (19%) radiologists had good 
agreement (0.8≥κ>0.6) and a further 12 (39%) had moderate agreement (0.6≥κ>0.4). 
Five (16%) radiologists had a fair agreement (0.4≥κ>0.2) and two had poor 
agreement (0.2>κ). There was a tendency towards good agreement (skewness: 
0.92). In 65.9% and 90% of cases the radiologists were able to correctly highlight 
good and poor responders, respectively. 
CONCLUSIONS: The assessment of the response of rectal cancers to 
chemoradiation therapy may be performed effectively using mrTRG. Radiologists 
can be taught the mrTRG scale. Even with minimal training, good agreement with 
the central reviewer along with effective differentiation between good and 
intermediate/poor responders can be achieved. Focus should be on facilitating the 
identification of good responders. It is predicted that with more intensive interactive 
cased-based learning a κ>0.8 is likely to be achieved. Testing and retesting is 
recommended.  
 
INTRODUCTION 
The treatment for rectal cancer has improved and has led to better survival 
outcomes over the last three decades. The reasons for this are multifactorial and 
include better understanding of pelvic anatomy1 and surgical techniques2, earlier 
diagnoses3, neoadjuvant or adjuvant therapies4, and improved imaging5. Response 
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of tumours to neoadjuvant therapy has also allowed more sphincter-sparing 
procedures6 with the additional potential for deferral of surgery 7,8.  
The degree of tumour response has been shown to be an important prognosticating 
factor 9,10. This response may be classified by several methods including: 
downstaging, most commonly according to the TNM classification11; downsizing, 
usually by Response Evaluation Criteria In Solid Tumours (RECIST)12; and, by 
regression grading13,14. Tumour regression appears to be an independent predictor 
for survival;1,15 however, there are several scales evident in the literature13,14,16-24. 
This has resulted in confusion as to the precise definition of a “poor”, “intermediate” 
or “good” responder;25 consequently, there is a wide variation in the reported 
disease-free survival (DFS) and overall survival (OS) 16,17,26-41.  
More recently magnetic resonance imaging (MRI) has been used for tumour 
regression grading (mrTRG) with a more representative DFS of 31–68% and OS 27–
59% for poor responders and DFS of 64–83% and OS of 72–90% for good 
responders 42,43. The mrTRG scale can be accurately taught and utilised by other 
experienced gastrointestinal radiologists44, achieving a κ of 0.6 for mrTRG, which 
was better than the interobserver agreement reported for T-staging at MRI 44. The 
purpose of this article is to investigate the interobserver agreement between a 
central reviewer and 35 radiologists newly taught in mrTRG assessment during a 
training workshop.  
 
MATERIALS AND METHODS 
Hypothesis and sample size 
The hypothesis of the present study was that the mrTRG scale can effectively be 
taught if a clinically reasonable interobserver agreement (κ>0.4; moderate to near 
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perfect agreement) was achieved and would be rejected if the agreement was κ<0.4 
(poor/fair agreement).  
The technique described by Gwet45 was used to determine the sample size, which 
assumes a chance probability of 0%. To achieve a minimum κ of 0.4 with a relative 
error of 20%, a minimum sample size of 156 is required. There were 35 radiologists 
at two separate workshops, and so a sample of 12 patients was chose, ensuring 420 
comparisons made with the central reviewer.  
 
Patients and imaging 
A senior radiologist reviewed a patient and imaging database at a cancer centre. 
Twelve patients with rectal cancer who had undergone long-course chemoradiation 
therapy (CRT) as part of their cancer treatment protocol between 2008 and 2013 
were included. Cases were selected if baseline and post-CRT (at 4-6 weeks) scans 
were available. The MRI images were examined to ensure a clear and fair 
representation of the mrTRG scale (Table 1). Anonymised scans were paired as pre- 
and post-treatment for assessment of levels of agreement. 
 
MRI protocol 
A 1.5 T MRI system with phased-array coils was used for all post-CRT scans. T2-
weighted large field of view (FOV) axial, and high-resolution small FOV sagittal, 
oblique axial (perpendicular to the lumen of rectal wall) and oblique coronal 
sequences were obtained. High-resolution MRI are defined as voxel size <1.5 and 
sufficient signal-to-noise ratio (SNR) 46. Pre-treatment scans were performed using a 
similar protocol. 
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Reference radiologist standard 
The reference standard for comparison was a senior radiologist with 20 years of 
reporting MRI examinations used to stage rectal cancer. The radiologist developed 
the mrTRG scale and routinely reported these imaging scans, which were previously 
performed with histopathological correlation 5. The same mrTRG scale was used by 
the central reviewer and the participating radiologists.  
 
Participating radiologists 
Thirty-five radiologists from Australia and New Zealand participated in two separate 
whole-day workshops on rectal cancer staging, including post-CRT assessment. The 
radiologists ranged from fellows to senior consultants. The participants included 
those with no experience in reporting rectal MRI to experienced gastrointestinal 
radiologists. None of the radiologists had prior experience of reporting using the 
mrTRG criteria. Delegates were not expected to be fully trained in mrTRG on 
completion, although an additional 30-minute case review session was provided after 
the assessment, which increased delegates’ levels of confidence and understanding. 
The workshop included a 15–30 minute lecture on the assessment of tumour 
characteristics after CRT, focusing on assessment according to the mrTRG scale. 
Following this, the radiologists assessed the pre- and post-treatment scans of 12 
patients and gave them an mrTRG score using a standardised proforma. The detail 
in the proforma used the same mrTRG scale (Fig. 1). The two proformas differed 
only in the first being more detailed, adding extra points that the radiologist could 
consider in their assessment of the case. The mrTRG score in both cases relied on 
the same tumour visible score, which is the information used to give the mrTRG 
score. There was a slight difference in the TRG score 2 between “minimal” and 
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“none” on first and second proformas, but the other scores were all unchanged. The 
additional points of fibrosis, mucin, and lymph nodes on the first proforma were for 
consideration only. On the second course, these were removed to encourage people 
to concentrate only on the relevant question of remaining tumour visible. No other 
pathological or clinical information was given to those participating. Images were 
assessed on a high-definition reporting monitor. The participants performed the 
assessment independently and were blinded to the correct assessment until the end 
of proforma completion. After handing in the proforma, the answers were available 
and several cases were reviewed in a group setting. No data were collected to 
identify individual radiologists. Completed data forms were collated and then 
compared to the reference standard assessment performed by a senior radiologist.  
 
mrTRG scale 
The mrTRG scale is based on a regression scale originally described for 
postoperative resection specimens13 and uses a five-point scale (Table 1) 42. Lower 
TRG scores refer to greater regression and the system further divides the categories 
into type of response (complete, good, moderate, slight, and none). Using the five-
point scale, mrTRG can classify response into good and poor according to survival 
outcomes 42-44,47. Good responders are those patients with mrTRG 1 and 2, whereas 
intermediate/poor responders are mrTRG 3–5 as defined for the purposes of this 
study. 
 
Data synthesis 
Data were tabulated and entered onto a spreadsheet. All statistical analyses were 
performed using Microsoft Excel version 14.4.5 (2011; Microsoft, Redmond, WA 
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USA) 48 and IBM SPSS version 22.0 (2013; IBM, NY, USA)49. Cohen’s κ level was 
used to calculate the interobserver agreement between the reference standard and 
individual radiologists and also to obtain an overall value. A value of p<0.05 was 
chosen as the significance level for κ statistics and tests whether the agreement is 
due to chance, therefore, if p<0.05 it proves the null hypothesis that the agreement 
would not be expected by chance alone50. The value of κ statistics was interpreted 
according to Altman51. Agreement lies between 0 and 1, where 0 is indicative of no 
agreement and 1 indicates complete agreement. “Very good/near perfect” 
agreement is considered as a κ of 0.81–1.00; “good” agreement as a κ of 0.61–0.80; 
“moderate” agreement as a κ of 0.41–0.60; “fair” agreement as a κ of 0.21–0.40; 
“poor” agreement as a κ of <0.2. Rarely, a negative κ is observed, which indicates 
that the interobserver agreement is less than would be expected by chance and is 
interpreted as no agreement52. A measure of skewness to assess normal distribution 
was calculated to investigate whether the trend was towards a higher or lower κ and 
considered significant if the standard error of the skewness was less than half the 
overall value of the skew53. Forest plots were used for graphical display using 
Comprehensive Meta-Analysis (Biostate, Englewood, NJ, USA)54. 
 
RESULTS 
Thirty-five radiologists completed the proforma for mrTRG scoring (Fig. 1). Two 
radiologists misunderstood the proforma (achieving a negative κ) and were excluded 
from the analysis. There were seven missing data entries leaving 389 assessments 
on 12 patients. There were six male and six female patient images. One patient had 
mrTRG 1, three had mrTRG 2, three had mrTRG 3, three had mrTRG 4, and two 
patients had an mrTRG5. This entailed four “good” responders (mrTRG 1–2) and 
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eight “intermediate/poor” responders (mrTRG 3–5) as defined for the purpose of this 
study.  
 
Patient demographics 
Patient demographics can be seen in Table 2. There were six men and six women. 
Mean age was 75 years (54–93 years). One patient had metastases at presentation 
and was a poor responder (mrTRG 4). Five patients were deferred for surgery, four 
of which were considered good responders (mrTRG 1 and 2). One patient (originally 
mrTRG 3) was deferred for surgery after a repeat MRI showed ongoing response. All 
patients who had a good response were given consolidation chemotherapy and 
underwent close follow-up.  
 
Ability to differentiate between good and intermediate/poor responders 
Results of the κ statistic for each radiologist can be seen in Table 3 and Fig. 2. Data 
from two radiologists were excluded because they misunderstood the proforma (κ = 
–0.04 and –0.24). Kappa agreement ranged from 0.14–0.82 with a median value of 
0.57 (confidence interval [CI]: 0.37–0.77) indicating an overall good agreement 
(weighted pooled κ was 0.63 as seen in Fig. 2). Eight (8/33; 26%) radiologists had 
very good/near perfect agreement (κ>0.8). Six (6/33; 19%) radiologists had good 
agreement (0.8>κ>0.6), and a further 12 (12/33; 39%) had moderate agreement 
(0.6>κ>0.4). Five (5/33; 16%) radiologists had a fair agreement, and two radiologists 
had a poor agreement. From the results there was a marked negative skew (–0.92, 
SE=0.40) indicating that the κ-values tended towards good agreement for mrTRG 
(Fig. 3). 
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Variation between workshops 
The median interobserver agreement from the first workshop was 0.61 (range=0.38–
0.82) and for the second it was 0.53 (range=0.14–0.80). As the comparisons were 
individual comparisons with the reference standard, it was not statistically feasible to 
directly compare the two; however, the difference does not constitute a drop in the 
kappa agreement categories and would be considered within an acceptable 
variance. 
 
Ability to identify good and poor responders as separate groups 
According to central review, there were four patients with mrTRG 1–2 (good 
responders); with 33 radiologists there were a total of 129 assessments (three 
assessments were missing). In 65.9% of cases, the radiologists were able to identify 
good responders correctly in agreement with the study standard. There were eight 
patients with mrTRG 3–5 (intermediate/poor responders); with 33 radiologists there 
were a total of 260 assessments (four assessments were missing). In 90% of cases, 
the radiologists were able to identify intermediate/poor correctly in agreement with 
the study standard. This suggests that radiologists are better at identifying poor 
responders than identifying good responders; this has a marked subsequent effect 
on the interobserver agreement. 
 
DISCUSSION 
Identifying an accurate and reproducible assessment of regression after CRT is an 
important factor in rectal cancer management. Although this has usually been 
conducted with pathological assessment systems, mrTRG has the advantage of 
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potentially affecting management prior to surgery, and therefore, provides a window 
of opportunity to act on this information. 
 
Main findings 
The present study has shown that after a short period of training, most radiologists 
were able to differentiate between good and intermediate/poor responders. Overall 
median κ agreement for differentiating good and intermediate/poor response was 
0.57 (0.37, 0.77). The relatively low standard error with narrow CIs indicates that 
these agreement levels are reproducible and result in clinically acceptable levels. 
Although 90% of radiologists were able to correctly identify intermediate and poor 
responders with scores of mrTRG3-5, only 66% correctly identified good responders. 
This indicates radiologists are more likely to misinterpret fibrosis as residual tumour 
and greater experience is necessary to have the confidence to report no visible 
tumour. 
 
Importance of this study 
Traditionally complete pathological response is considered to be reflective of better 
long-term outcomes 15. There has been extensive work on attempting to classify 
patients into good and intermediate/poor response to try and personalise treatment 
options and inform follow-up protocols; however, this has remained challenging due 
to a range of pTRG scales that assess regression55 using post-surgical specimens 
13,14,16-23
. Although traditionally histopathology was considered the reference 
standard, a reference standard is typically defined as any technique that predicts 
outcomes accurately. mrTRG has shown better correlation to survival outcomes in 
the literature, and therefore, is an important tool in directing treatment, and currently, 
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would be viewed as the preferred reference standard. Given the role of mrTRG, it 
would be useful to establish whether it can be taught and utilised effectively by other 
radiologists. The present study has shown that good clinical κ agreement can be 
achieved with minimal training. Further focus could concentrate on facilitating the 
ability to identify good responders. 
 
Appraisal of evidence 
The results of the present study are comparable with other studies, including the 
MERCURY study,43,44 reporting κ agreement of 0.55–0.65. The present results were 
not dissimilar to these values, and this highlights that the mrTRG scale can be 
replicated in a range of settings and may be taught effectively by the techniques of 
standalone workshops; essentially validating its use by other radiologists in different 
settings.  
Furthermore the present study has shown that mrTRG is consistent and reliable in 
differentiating between good and intermediate/poor responders. This is higher than 
reported histological grading systems, which tend toward poor agreement using 
different histological scales with overall κ values ranging from 0.28–0.38 and 
approximate median κ values for different scales of 0.24, 0.42, and 0.58 56. One 
issue regarding pathology TRG scales is that there is a perception that it may not 
actively affect the ongoing management of patients despite its mandatory 
requirement in reports 57. The use of mrTRG allows the multidisciplinary team (MDT) 
to potentially change management decisions preoperatively and consider the use of 
consolidation chemotherapy and non-operative therapy 58.  
 
Strengths of the study 
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The main strength of the present study is the sample size of 35 radiologists and 12 
patient images giving an effective sample size of 413 (seven missing assessments). 
This ensured effective statistical analyses to be performed. The teaching setting was 
part of a workshop attended by radiologists who had an interest in learning or 
improving their skills in reporting rectal cancer MRI, but none had prior experience in 
using this mrTRG system. The images were high quality and assessed on reporting 
monitors, allowing the assessments to be performed according to the mrTRG scale 
without any confounding image-related factors. The radiologists were also blinded to 
the reference standard until the end of the assessment. The advantage of 
establishing mrTRG as the reference standard assessment is to effectively offer 
management specifically tailored to patients and may include the option of non-
operable management or potentially further chemoradiotherapy, with a view to 
increasing sphincter-saving procedures. 
 
Limitations and heterogeneity of this study 
The short period of teaching and assessment may falsely downgrade the κ 
agreement. Ideally, the assessment could be extended to multiple workshops with an 
initial period of central review, as there is likely to be a learning curve,43 even though 
the initial results are encouraging. As part of a full-day course on rectal MRI staging, 
the mrTRG was only presented as a brief lecture and there was no hands-on case-
based teaching until after the assessments had been completed. The lecture and 
proforma were also altered slightly between the two workshops. The radiologists had 
differing degrees of experience, including some who had no prior experience 
reporting rectal MRI, which may reflect the range of agreement for individual 
radiologists.  
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The costs of MRI following treatment may not always be reimbursed in different 
healthcare systems. Rationing of healthcare spending and limitation of MRI 
examinations until the test can be proven definitively as a clinical necessity is also a 
factor in some centres. The lack of confidence in radiological interpretation of post-
treatment imaging has also been cited as a contributing factor 59,60.  
 
Implications for clinical practice and future work 
The present study indicated that post-treatment assessment of tumour regression 
(mrTRG) can be taught effectively in a short time period and as the body of evidence 
increases regarding patient assessment using MRI, subsequent implementation and 
adoption of the mrTRG scale may be relatively seamless. The use of mrTRG-
directed management to offer this stratified approach to treatment will be tested in 
the multicentre randomised TRIGGER trial (magnetic resonance Tumour Regression 
Grade (mrTRG) as a novel biomarker to stratify between Good and poor responders 
following chemoradiotherapy in Rectal cancer). This imminent trial will investigate the 
initial MRI to guide neoadjuvant therapy requirement and operative planning, 
including influencing factors such as mrEMVI. A second MRI after neoadjuvant 
therapy will examine mrTRG. A good responder may be offered deferral of surgery 
and the poor responders will be offered further treatment or surgery. 
 
In conclusion, the assessment of the response of rectal cancers to chemoradiation 
therapy may be performed effectively using mrTRG. Radiologists can be taught the 
mrTRG scale. Even with minimal training, good agreement levels with the central 
reviewer along with effective differentiation between good and intermediate/poor 
responders can be achieved. Focus should be on facilitating the identification of 
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good responders. It is predicted that with more intensive interactive cased-based 
learning a κ>0.8 is likely to be achieved. Testing and retesting is recommended.  
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Table 1 – Summary of magnetic resonance imaging (MRI) tumour regression scale 
(mrTRG). 
TRG 
scale 
mrTRG 
(low no.=more regression) 
1 No/minimal fibrosis visible (tiny linear scar) and no tumour signal 
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2 Dense fibrotic scar (low signal intensity) but no macroscopic tumour 
signal (indicates no or microscopic tumour) 
3 
Fibrosis predominates but obvious measureable areas of tumour 
signal visible 
 4 Tumour signal predominates with little/minimal fibrosis 
5 Tumour signal only: no fibrosis, includes progression of tumour 
 
 
Table 2. Patient demographics 
Study 
ID 
mrTRG Sex Age 
Date of 
diagnosis 
Metastases 
presentation 
Deferred 
for good 
response 
Further  
treatment 
(chemo) 
Operated 
1 3 F 72 01/11/11 No No No Yes 
2 4 M 86 01/03/11 Yes No Yes Yes 
3 3 F 93 14/04/11 No Yes No No 
4 5 F 70 01/11/12 No No Yes No 
5 1 F 69 08/11/11 No Yes Yes No 
6 2 F 67 28/05/10 No Yes Yes Yes 
7 4 M 73 01/06/12 No No No No 
8 4 F 88 29/05/13 No No No Yes 
9 5 M 81 12/07/12 No No Yes No 
10 2 M 81 18/04/11 No Yes Yes No 
11 3 M 54 10/05/11 No No No Yes 
12 2 M 67 26/08/08 No Yes Yes Yes 
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Table 3. Interobserver agreement for radiologists’ ability to identify good and poor 
responders 
Radiologist Kappa S.E Confidence interval p-Value 
1 0.82 0.17 0.48, 1.16 <0.001 
2 0.38 0.31 –0.24, 0.99 0.24 
3 0.80 0.19 0.42, 1.18 <0.01 
4 0.53 0.30 –0.06, 1.12 0.11 
5 0.80 0.19 0.42, 1.18 <0.01 
6 0.82 0.17 0.48, 1.16 <0.001 
7 0.61 0.25 0.10, 1.11 <0.05 
8 0.53 0.30 –0.06, 1.12 0.11 
9 0.63 0.24 0.14, 1.11 <0.05 
10 -0.04 0.34 –0.72, 0.65 1.00 
11 0.61 0.25 0.10, 1.11 <0.05 
12 0.40 0.30 –0.2, 1.00 0.21 
13 0.40 0.30 –0.2, 1.00 0.21 
14 0.79 0.20 0.40, 1.19 <0.01 
15 0.53 0.24 0.07, 1.00 <0.05 
16 0.63 0.24 0.16, 1.10 <0.05 
17 0.53 0.24 0.07, 1.00 <0.05 
18 0.31 0.35 –0.37, 0.99 0.39 
19 0.80 0.19 0.43, 1.17 <0.01 
20 0.57 0.28 0.03, 1.11 0.06 
21 0.80 0.19 0.43, 1.17 <0.01 
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22 0.25 0.31 –0.35, 0.85 0.43 
23 0.57 0.28 0.03, 1.11 0.06 
24 0.56 0.28 –0.003 :1.12 0.08 
25 0.63 0.24 0.16, 1.10 <0.05 
26 0.80 0.19 0.43, 1.17 <0.01 
27 0.25 0.31 –0.35, 0.85 0.43 
28 0.14 0.35 –0.55, 0.83 0.69 
29 0.40 0.30 –0.19, 0.99 0.21 
30 0.57 0.28 0.03, 1.11 0.06 
31 0.31 0.35 –0.37, 0.99 0.39 
32 -0.24 0.30 –0.83, 0.35 0.43 
33 0.14 0.35 –0.55, 0.83 0.69 
34 0.80 0.19 0.43, 1.17 <0.01 
35 0.40 0.30 –0.19, 0.99 0.21 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Highlights: 
• Inter-observer agreement of radiologists was assessed, when using the MRI tumour 
regression scale to determine response of rectal cancers to chemoradiotherapy 
• Kappa agreement had a median value of 0.57 (95% CI: 0.37-0.77) indicating an overall 
good agreement.  
• In 65.9% and 90% of cases the radiologists were able to correctly highlight good and 
poor responders respectively. 
• Radiologists can be taught the mrTRG scale and even with minimal training good 
agreement and effective differentiation between good and intermediate/poor responders 
can be achieved.  
• Focus should be on facilitating the identification of good responders.  
